Compare · POCI vs SLNO
POCI vs SLNO
Side-by-side comparison of Precision Optics Corporation Inc. (POCI) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POCI and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 57.9x POCI ($47.7M).
- POCI has hit the wire 6 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for POCI).
- Company
- Precision Optics Corporation Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- $47.7M
- $2.76B
- 1M return
- -
- +0.76%
- 1Y return
- -
- -18.97%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest POCI
- Amendment: SEC Form 4/A filed by Precision Optics Corporation Inc.
- Chief Financial Officer Coll Wayne M was granted 6,250 shares, increasing direct ownership by 16% to 46,218 units (SEC Form 4)
- Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference
- Precision Optics Corporation Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results
- SEC Form 10-K filed by Precision Optics Corporation Inc.
- Chief Operating Officer Traut Joseph was granted 6,742 shares, increasing direct ownership by 16% to 48,408 units (SEC Form 4)
- Chief Executive Officer Forkey Joseph Norman was granted 6,742 shares, increasing direct ownership by 5% to 150,701 units (SEC Form 4)
- Chief Financial Officer Coll Wayne M was granted 6,742 shares, increasing direct ownership by 18% to 44,806 units (SEC Form 4)
- Precision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)